Dravet syndrome (DS), or severe myoclonic epilepsy of infancy, is a rare form of epilepsy affecting less than one in 10,000 people in the United States. However, in affected children, the condition can delay normal development and affect lifelong outcomes.
Like many rare diseases, Dravet syndrome still has no cure, but a study recently published in the Journal of Clinical Investigation and conducted by several research teams, including one led by Eric Kremer at IGMM, hopes to change that. The researchers show that gene therapy successfully reduces seizures in a mouse model of Dravet syndrome, making it a potential path to a cure.
More information : Defending against Dravet (the-scientist.com)
